Winston Pharmaceuticals, Inc. Announces Re-Election of Joel E. Bernstein M.D. as President and Chief Executive Officer
15 8월 2009 - 5:00AM
Business Wire
Winston Pharmaceuticals, Inc. (OTC BB: WPHM) (the “Company”)
today announced that Joel E. Bernstein, M.D., the founder of
Winston Laboratories, Inc., the Company’s wholly-owned subsidiary,
will remain as President and Chief Executive Officer of the Company
for the duration of the term set forth in his employment agreement
with the Company (the “Employment Agreement”).
On August 7, 2009, Dr. Jeffrey R. Bernstein, Ph.D., who had
previously been chosen by the Company’s Board of Directors (the
“Board”) to succeed Dr. Joel Bernstein as President and Chief
Executive Officer of the Company effective September 22, 2009,
withdrew as a candidate for the position. Following further
deliberations, the Board determined that it was in the Company’s
best interests for Dr. Joel Bernstein to remain as its President
and Chief Executive Officer of the Company for the duration of the
term set forth in his Employment Agreement. Accordingly, on August
14, 2009, with the agreement of Dr. Joel Bernstein, who rescinded
his resignation, the Board reelected Dr. Joel E. Bernstein as
President and Chief Executive Officer of the Company subject to the
provisions set forth in his Employment Agreement.
The Board ratified and confirmed its prior determination that
Robert A. Yolles shall succeed Dr. Joel E. Bernstein as the
Chairman of the Board effective September 22, 2009.
About Winston Pharmaceuticals
Winston Pharmaceuticals, Inc. is a development stage
pharmaceutical company focused on pain control. The Company is
developing products for large pain control markets, as well as for
niche markets, where there are still significant unmet needs for
pain management options with improved efficacy, safety, and
tolerability profiles. The Company’s product candidates span a
range of pain indications, including arthritis, neuropathic pain,
cancer pain, post-operative pain, cluster headache and chronic
daily headache.
This press release contains “forward-looking statements,” as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), regarding product development efforts and
other non-historical facts about expectations, beliefs or
intentions regarding the business, technologies and products,
financial condition, strategies or prospects. Many factors could
cause actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements.
These factors include those described in our filings with the
Securities and Exchange Commission, as well as risks inherent in
funding, developing and obtaining regulatory approvals of new,
commercially-viable and competitive products and treatments,
including the risks that any products under development may fail,
may not achieve the expected results or effectiveness and may not
generate data that would support the approval or marketing of
products for the ailments being studied or for other ailments. In
addition, forward-looking statements also may be adversely affected
by general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. We do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the
PSLRA.
Winston Pharmaceuticals (CE) (USOTC:WPHM)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Winston Pharmaceuticals (CE) (USOTC:WPHM)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
